Paper95205
Augmentation by interferon of human natural and antibody-dependent cell-mediated cytotoxicity.
Herberman RR and 2 others. Nature, 1979. Cited by 572 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Augmentation by interferon of human natural and antibody-dependent cell-mediated cytotoxicity. Papers, record 95205. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/95205
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Augmentation by interferon of human natural and antibody-dependent cell-mediated cytotoxicity.
- PubMed
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antibody-Dependent Cell Cytotoxicity | Major topic |
| Cytotoxicity, Immunologic | Major topic |
| Immunity, Innate | Major topic |
| Interferons | Major topic |
| Antigen-Antibody Reactions | |
| Humans | |
| Killer Cells, Natural |
Source PubMed
Cited by111
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 572 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 37,456,846 | CSL362 potently and specifically depletes pDCs invitro and ablates SLE-immune complex-induced IFN responses. | iScience | 2023 | https://conductscience.org/library/papers/37456846 | PubMed |
| 35,931,666 | Reactive oxygen species-responsive and Raman-traceable hydrogel combining photodynamic and immune therapy for postsurgical cancer treatment. | Nat Commun | 2022 | https://conductscience.org/library/papers/35931666 | PubMed |
| 35,466,184 | Prompt Hematological Recovery in Response to a Combination of Pegylated Interferon α-2a and Rituximab in a Profoundly Immuno-Suppressed Hairy Cell Leukemia Patient with a Mycobacterial Infection at Onset: Benefits and Drawbacks of Rapid Immune Reconstitution. | Hematol Rep | 2022 | https://conductscience.org/library/papers/35466184 | PubMed |
| 35,327,405 | Influence of Fetomaternal Microchimerism on Maternal NK Cell Reactivity against the Child's Leukemic Blasts. | Biomedicines | 2022 | https://conductscience.org/library/papers/35327405 | PubMed |
| 33,304,763 | Engineering Prodrug Nanomedicine for Cancer Immunotherapy. | Adv Sci (Weinh) | 2020 | https://conductscience.org/library/papers/33304763 | PubMed |
| 31,798,596 | 29-Color Flow Cytometry: Unraveling Human Liver NK Cell Repertoire Diversity. | Front Immunol | 2019 | https://conductscience.org/library/papers/31798596 | PubMed |
| 30,932,943 | Defective FasL expression is associated with increased resistance to melanoma liver metastases and enhanced natural killer cell activity. | Melanoma Res | 2019 | https://conductscience.org/library/papers/30932943 | PubMed |
| 30,531,990 | In situ sprayed bioresponsive immunotherapeutic gel for post-surgical cancer treatment. | Nat Nanotechnol | 2019 | https://conductscience.org/library/papers/30531990 | PubMed |
| 29,577,477 | Neutrophil-Based Drug Delivery Systems. | Adv Mater | 2018 | https://conductscience.org/library/papers/29577477 | PubMed |
| 29,213,274 | Natural Killer Cells in Antifungal Immunity. | Front Immunol | 2017 | https://conductscience.org/library/papers/29213274 | PubMed |
| 28,928,751 | "Multi-Omics" Analyses of the Development and Function of Natural Killer Cells. | Front Immunol | 2017 | https://conductscience.org/library/papers/28928751 | PubMed |
| 24,188,121 | Human immune responses to Plasmodium falciparum infection: molecular evidence for a suboptimal THαβ and TH17 bias over ideal and effective traditional TH1 immune response. | Malar J | 2013 | https://conductscience.org/library/papers/24188121 | PubMed |
| 24,154,599 | Genetic and environmental determinants of human NK cell diversity revealed by mass cytometry. | Sci Transl Med | 2013 | https://conductscience.org/library/papers/24154599 | PubMed |
| 19,276,249 | The antitumor and immunoadjuvant effects of IFN-alpha in combination with recombinant poxvirus vaccines. | Clin Cancer Res | 2009 | https://conductscience.org/library/papers/19276249 | PubMed |
| 17,675,184 | Alphaviral vector-transduced dendritic cells are successful therapeutic vaccines against neu-overexpressing tumors in wild-type mice. | Vaccine | 2007 | https://conductscience.org/library/papers/17675184 | PubMed |
| 9,536,127 | Cathepsin G enhances human natural killer cytotoxicity. | Immunology | 1998 | https://conductscience.org/library/papers/9536127 | PubMed |
| 9,203,979 | Induction of the 2B9 antigen/dipeptidyl peptidase IV/CD26 on human natural killer cells by IL-2, IL-12 or IL-15. | Immunology | 1997 | https://conductscience.org/library/papers/9203979 | PubMed |
| 8,705,672 | Determination of natural killer cell function by flow cytometry. | Clin Diagn Lab Immunol | 1996 | https://conductscience.org/library/papers/8705672 | PubMed |
| 8,439,987 | Mechanism of stimulation of human natural killer cytotoxicity by arabinogalactan from Larix occidentalis. | Cancer Immunol Immunother | 1993 | https://conductscience.org/library/papers/8439987 | PubMed |
| 8,439,976 | Enhancement of the antibody-dependent cellular cytotoxicity of human peripheral blood lymphocytes with interleukin-2 and interferon alpha. | Cancer Immunol Immunother | 1993 | https://conductscience.org/library/papers/8439976 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/95205
GET https://conductscience.org/api/papers/v1/95205/cited_by?page=2